JPRN-jRCT2031200409招募中未知
Special drug use-results surveillance of Tabrecta Tablets (MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancer)
Sugimoto Toshiya0 个研究点目标入组 100 人开始时间: 2021年3月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period
排除标准
- 未提供
研究者
相似试验
招募中
Unknown
Post-marketing Surveillance Protocol Number; CDRB436I1401BRAF V600E mutation-positive unresectable advanced or recurrent solid tumorJPRN-jRCT2031230623sato masayuki90
已完成
不适用
Special Drug Use-results Surveillance of Tabrecta TabletsNon-small Cell Lung CancerNCT04575025Novartis Pharmaceuticals109
招募中
Unknown
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100
未知
Unknown
Drug use surveillance of Takecab for Supplement to Helicobacter pylori eradicatioThe following diseases in patients for whom H. pylori will be eradicated with triple therapy: Gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, stomach following endoscopic treatment of early gastric cancer, or H. pylori gastritisJPRN-jRCT1080222951TAKEDA PHARMACEUTICAL COMPANY LTD.500
招募中
不适用
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3